Scientists from the French University of Paris-Est Creteil, as part of a scientific team, discovered that drugs based on female steroid hormones from the progestogen class can increase the risk of developing meningoma, a type of brain tumor. Research results published In BMJ.
The scientific study used data from more than 18 thousand women (average age 58) who had surgery to remove intracranial meningioma between 2009 and 2018. Information on the topics was taken from the archives of the French National Health System (SNDS). The study also included information on 90,305 healthy women.
Scientists tried to find out how taking progestogens (progesterone, hydroxyprogesterone, dydrogesterone, medrogestone, promegestone and levonorgestrel and other drugs) affects the risk of developing meningoma. This (mostly) benign tumor of the meninges can compress nerve tissue, impairing its function.
The results showed that long-term use of the drug medrogestone (a year or longer) was associated with a more than fourfold increase in the risk of developing intracranial meningioma requiring surgery. Medroxyprogesterone increased the likelihood of developing this type of tumor by 5.6 times, and promegestone – by 2.7 times.
Potential meningoma triggers included chlormadinone acetate, nomegestrol acetate, and cyproterone acetate. However, the ability of progesterone and dydrogesterone drugs to affect tumor growth has not been demonstrated.
The researchers say their findings should be interpreted with caution. It cannot be said with certainty that taking progestogen causes meningoma. Other factors, including genetic predisposition, may be potential causes of its development.
Previously in cancer cells to create A new difference from healthy people.
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.